Key Points
- Gilead insider Johanna Mercier sold 3,000 shares on June 15 at an average price of $123.92, totaling $371,760. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and her ownership fell by 2.36%.
- Gilead recently reported better-than-expected quarterly earnings, with EPS of $2.03 versus estimates of $1.91 and revenue of $6.96 billion, up 4.4% year over year. The company also declared a quarterly dividend of $0.82 per share, yielding about 2.6% annually.
- Analyst sentiment remains mostly positive, with 25 Buy ratings and a consensus rating of Moderate Buy. Recent news also highlighted FDA acceptance of Gilead’s filing for once-weekly oral Yeztugo for HIV prevention, a potential future growth driver.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the transaction, the insider owned 124,234 shares of the company's stock, valued at $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Johanna Mercier also recently made the following trade(s):
- On Friday, May 15th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00.
- On Wednesday, April 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $140.96, for a total value of $422,880.00.
Gilead Sciences Trading Up 2.4%
GILD stock opened at $127.23 on Wednesday. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The company has a market capitalization of $157.96 billion, a price-to-earnings ratio of 17.33 and a beta of 0.31. The business has a 50 day simple moving average of $132.61 and a two-hundred day simple moving average of $134.32.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the prior year, the company posted $1.81 EPS. The firm's revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.
Gilead Sciences Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences's dividend payout ratio is presently 44.69%.
Analyst Ratings Changes
A number of research analysts have recently commented on the company. Wall Street Zen downgraded Gilead Sciences from a "strong-buy" rating to a "hold" rating in a research report on Saturday, May 9th. Royal Bank Of Canada reiterated a "sector perform" rating on shares of Gilead Sciences in a research report on Monday, June 8th. Mizuho increased their target price on Gilead Sciences from $140.00 to $170.00 and gave the company an "outperform" rating in a research report on Wednesday, February 18th. Jefferies Financial Group assumed coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a "buy" rating and a $180.00 target price for the company. Finally, Truist Financial reiterated a "buy" rating and set a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $158.41.
Read Our Latest Stock Report on Gilead Sciences
Institutional Trading of Gilead Sciences
A number of institutional investors have recently bought and sold shares of the stock. Paulson Wealth Management Inc. lifted its position in Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company's stock worth $477,000 after buying an additional 67 shares during the last quarter. Essex Financial Services Inc. lifted its position in Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company's stock worth $948,000 after buying an additional 71 shares during the last quarter. Davidson Trust Co. lifted its position in Gilead Sciences by 4.1% in the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company's stock worth $262,000 after buying an additional 74 shares during the last quarter. Alpha Cubed Investments LLC lifted its position in Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company's stock worth $812,000 after buying an additional 75 shares during the last quarter. Finally, Personal CFO Solutions LLC lifted its position in Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company's stock worth $561,000 after buying an additional 76 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.
Key Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
